Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 60760-877

6 FDA label images from St. Mary's Medical Park Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 60760-877). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

877-60 (Esomeprazole Magnesium Dr 20mg 60ct 60760 877 60)

877-60 (Esomeprazole Magnesium Dr 20mg 60ct 60760 877 60)
Esomeprazole Magnesium 20 mg delayed-release capsules label showing product name, strength, dosage form, and quantity of 60 capsules. Label includes storage instructions (20° to 25°C), pharmacist dispensing guidance, and contact information. Manufactured by Annora Pharma Pvt. Ltd., India, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, Arizona.*
FDA Label Image

Esomeprazolemagnesiumfigure1 (Esomeprazolemagnesiumfigure1)

Esomeprazolemagnesiumfigure1 (Esomeprazolemagnesiumfigure1)
Chemical structure of Esomeprazole Magnesium showing its molecular arrangement with magnesium ion and water molecules, as used in the 20 mg delayed release oral capsules by St. Mary's Medical Park Pharmacy.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the percentage maintained over a 6-month period for Esomeprazole Magnesium delayed-release capsules at 40 mg, 20 mg, and 10 mg doses compared to placebo. The x-axis represents months, and the y-axis represents the percent maintained, with data points connected by lines showing higher percentages maintained by the 40 mg dose and lowest by placebo.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph showing the percentage maintained over 6 months for Esomeprazole Magnesium Delayed-Release Capsules at 40 mg, 20 mg, and 10 mg doses compared to placebo. The x-axis represents time in months, and the y-axis represents percent maintained. The 40 mg dose maintains close to 100% over time, followed by the 20 mg and 10 mg doses with decreasing trends, while placebo shows the lowest maintenance percentages.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph depicting the percentage of patients symptom-free over 28 days, comparing Esomeprazole Magnesium Delayed-Release Capsules at 20 mg and 40 mg doses to a placebo. The x-axis represents diary days from 0 to 28, and the y-axis shows the percent of patients symptom-free from 0% to 100%. Both Esomeprazole doses show higher symptom-free rates than placebo throughout the period.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph showing the percentage of patients symptom-free over a 28-day diary period for Esomeprazole Magnesium delayed-release capsules 20 mg and 40 mg compared to placebo. The x-axis represents diary days, and the y-axis shows the percent of patients symptom-free, with both dosages showing higher symptom-free rates than placebo throughout the period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.